NCT05470829 - A Multiple-dose Study in Chinese Subjects to Evaluate Safety,Tolerability,PK and PD of ZM-H1505R | Biotech Hunter

Enrollment

42

Participants

Timeline

Start Date

May 27, 2021

Primary Completion Date

November 17, 2021

Study Completion Date

November 17, 2021

Conditions

Healthy VolunteersHepatitis B, Chronic

Interventions

DRUG

ZM-H1505R

"Part 1 dosage form:75mg dosage:Tablet frequency: Quaque die duration: Day1; Day 4\~ Day 14~Cohort 1 of Part 2 dosage form:50mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28~Cohort 2 of Part 2 dosage form:100mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28~Cohort 3 of Part 2 dosage form:200mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28"

OTHER

ZM-H1505R Placebo

"Part 1 dosage form:75mg dosage:Tablet frequency: Quaque die duration: Day1; Day 4\~ Day 14~Cohort 1 of Part 2 dosage form:50mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28~Cohort 2 of Part 2 dosage form:100mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28~Cohort 3 of Part 2 dosage form:200mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28"

Trial Locations (1)

Unknown

The First Hospital of Jilin University, Changchun